Filing Flows › Nektar Therapeutics (NKTR) › Q1 2025
Nektar Therapeutics (NKTR) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 9, 2025
Nektar Therapeutics (NKTR) reported revenue of $10.5M for the first quarter 2025 (Q1 2025), -52% from a year earlier and -64% from the quarter before. Operating margin was -425.8%, net loss $50.9M (486.4% of revenue).
Nektar Therapeutics, Q1 2025: revenue $10.5M (-52% year over year), operating margin -425.8%, net loss $50.9M, operating cash flow −$49.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.5M | -64% | -52% |
| Operating profit | −$44.5M | -410% | — |
| Net earnings | −$50.9M | -801% | — |
| Operating cash flow | −$49.1M | — | — |
What changed
Revenue was $10.5M in Q1 2025, down 52% year over year and down 64% from the previous quarter.
Operating costs exceeded revenue by $44.5M, an operating margin of -425.8%. Total costs fell 4% while revenue fell 52%. The fastest-growing cost line was General & admin (+21%). The quarter ended with a net loss of $50.9M, after a profit of $7.3M the previous quarter.
Operating cash flow was −$49.1M. Non-cash charges added back $426K of depreciation and amortization and $3.9M of share-based compensation. Working capital and other items used $2.5M. Capital expenditures of $2K exceeded it, leaving free cash flow of −$49.1M.
Questions
What was Nektar Therapeutics' revenue in the first quarter 2025?
Nektar Therapeutics (NKTR) reported revenue of $10.5M for the first quarter 2025 (Q1 2025), -52% from a year earlier and -64% from the quarter before.
Was Nektar Therapeutics profitable in the first quarter 2025?
Operating loss was $44.5M (-425.8% of revenue) and net loss $50.9M.